Tufts Center for the Study of Drug

DiMasi JA. Risks in new drug development Approval success rates for investigational drugs. Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, 2001. 

Tufts Center for the Study of Drug Development, Tufts CSDD Impact Report, 2005,1—4. 

Reichert, J.M. and Milne, C.-P., Public and private sector contributions to the discovery and development of "impact" drugs, A Tufts Center for the Study of Drug Development White Paper, May 2002. 

Sources. (1) PhRMA (Pharmaceutical Research and Manufacturers of America) Press Release dated November 14, 2006. http //www.who.int/mediacentre/factsheets/fs310/en/ index.html [accessed April 19, 2007], (2) CNN.com. Largest Passenger Jet Unveiled, January 18,2005. http //www.cnn.eom/2005/BUSINESS/01/18/airbus.380/ [accessed April 19, 2007], (3) Tufts Center for the Study of Drug Development, http //www.bizjournals.com/ sanfrancisco/stories/2006/12/04/newscolumn3.html [accessed September 26,2007]. 

Tufts Center for the Study of Drug Development. 2003. Total Cost to Develop a New Prescription Drug, Including Cost of Post-Approval Research, Is 897 mUlion. Press release, May 13, 2003. Available at www.csdd.tufts.edu. 

Tufts Center for the study of Drug Development http //csdd.tufts.edu/... 

Grabowki, H., J. Dimasi, and R. Hansen. 2004. Assessing Claims about the Cost of New Drug Development A Critique of the Public Citizen and TB Alliance, 1-20. Tufts Center for the Study of Drug Development. Available at http //csdd.tufts.edu/ documents/www/Doc 231 45 735. pdf [Accessed May 10, 2005]. 

Courses/ workshops/ and meetings are offered by the Pharmaceutical Education and Research Institute (PERI) (46)/ Drug Information Association (DIA) (47)/ Center for Drug Development Science (CDDS) at the University of California/ San FranciscO/ Washington/ D.C. Center (48)/ Tufts Center for the Study of Drug Development (CSDD-Tufts) (49)/ the National Institutes of Health (50)/ the FDA s Center for Drug Evaluation and Research (CDER)/ and other organizations. 

Tufts center for the study of drug development. In Backgrounder How New Drugs Move Through the Development and Approval Process, Tufts Centa for the study of Drug Development Boston, MA, 2001. 

Second, the percentage of US investigators participating in clinical trials has always been low, in the range of 5% of physicians, and this number seems to be declining. A recent study from the Tufts Center for the Study of Drug Development indicates that only 3% of US board certified physicians are principal investigators (Tufts University, 2005). 

Tufts Center for the Study of Drug Development. User Fees Credited with 51 % Drop in Average Approval Times Since 1993. In Tufts Center for the Study of Drug Development Impact Report ,, Iune 1999, Available at http // www.tufts.edu/med/csdd/impactl2.pdf. Accessed 2/22, 2001. 

Dimasi, J. A. 2001. The economics of pharaceutical innovation New estimates of drug development costs. Tufts Center for the Study of Drug Development 25th Anniversary Forum (Philadelphia, PA, USA). 

J.M. Reichert, Protein therapeutic success rates increase with biotech advances. Tufts center for the study of drug development impact report 2005, 7. 

---